posted
RPRX crashed after they released news about their drug Proellex causing increased liver enzymes in their 50mg dose. Since that news was released, the company has discontinued testing the 50mg dose and has moved forward with the two smaller doses of 25 and 12 mg. The smaller doses have shown no adverse effects and have been just as sucessful in treatment.
As it stands now, the stock is way oversold. It took a huge hit on the initial news about the liver problems with the high dose. But the stock began to climb until the same news was released again and the stock tumbled for no reason.
This stock is trading 3% above it's 52 week low after crashing, there is huge upside potential here. RPRX is moving along into Phase III trials on the smaller doses with results expected in Q4. They also have another Phase III trial on a different drug which will be completed Q1 2010.
This stock could very easily bounce from $2.50 back up to 6-7$ on no news. Once they issue positive news about Proellex, don't be surprised to see this stock trading back over $15. Anyone who watches biotech stocks knows how quickly these stocks move once a drug is approved.
Take some time to read some of the PR's about the issue with the high dose of Proellex and you should see that the 25mg dose is just as effective, but without any side effects. So it's like nothing has changed. The drug is extremely effective, they just ditched the 50mg dose. Once people wake up and see that nothing has really changed, this stock is going to move fast.
IP: Logged |
posted
Have you been watching the trades for the past couple days? The MM's are really trying to hold this back. Lots of blocks of 100 shares trading at the bid. Every time an ask order go's through, a 100 share order follows at the bid. It's an obvious indication that the MM's are loading up. Because as you mentioned there was no reason for the second drop in pps from $7 to $2. And the stock is a huge bargain at $2.50. I was able to get in * $2.35 a couple days ago. Depending on how it moves today, I might buy some more at the end of the day. I hate when people say "this is going to be the next ------". But I really feel that this could be the next DNDR or HGSI. The low float will help out when this begins to climb. It will be hard to hold it back. Playing the biotechs is the best game in town. Even if this stock doesn't interest you, you should be trading biotech stocks. I've been making a killing on them. ACAD , SQNM , HGSI ......ect.
IP: Logged |
Repros Suspends Proellex Trial, Faces Liquidity CrunchLast update: 8/3/2009 9:37:04 AM DOW JONES NEWSWIRES Repros Therapeutics Inc. (RPRX) suspended dosing in clinical trials of its Proellex drug for uterine fibroids and endometriosis after late last month reporting significantly higher levels of liver enzymes in patients at higher doses. The pharmaceuticals development company also said it is considering various funding options to address its immediate short-term liquidity needs. Shares plunged 60% in early trading to $1.03 as Repros said if funding is unavailable, steps up to a bankruptcy filing or liquidation would be considered. The stock fell 58% in July after the company revealed liver problems linked to higher doses of Proellex. Shares are off 90% this year. Many drug developers have run into liquidity problems since the credit crunch, with some of them being snapped up by major pharmaceutical companies looking to beef up their development pipelines. Repros said Monday it plans to discuss safety issues regarding Proellex with the Food and Drug Administration in late September, as well as the direction for the program that began nearly two years ago. The company, which has been posting losses for years, said any new financing is likely to result in significant dilution of current shareholders. If Repros cannot obtain financing, it will consider a number of options, such as cost cutting, a sale of the company, licensing or selling assets or a possible bankruptcy filing or liquidation. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; tess.stynes*dowjones.com (END) Dow Jones NewswiresAugust 03, 2009 09:37 ET (13:37 GMT)
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
